INTRODUCTION

The Gram-negative spirochaete and pathogen Helicobacter pylori (H. pylori) may have originated in Africa 58,000 years ago (15). H. pylori was first reported in 1875, when Bottcher and Letulle observed it on margins of peptic ulcers. However, its role in gastrointestinal diseases was not demonstrated until 1983, a discovery which earned Warren and Marshall a Nobel Prize in Physiology or Medicine in 2005 and rekindled interest in the study of this microorganism. Since then, the association of H. pylori and digestive tract diseases has been object of much research (13).

LITERATURE

The presence of H. pylori in gastroduodenal mucosa and its involvement in the development of chronic gastritis, carcinoma, lymphoma and other illnesses are well documented. Moreover, a strong link exist between peptic ulcer disease and H. pylori infection (12). However, the role of H. pylori in the human organism is not fully understood (10). Recently, the presence of H. pylori in gall bladder mucosa was found to be associated with development of chronic calculous cholecystitis. In fact, H. pylori may be the cause of the chronic inflammation observed in this condition (7). The preliminary results of a Chinese study showed that the infection with H. pylori (especially of the CagA serotype) is a significant risk factor for development of pancreatic cancer (2). On the other hand, some authors have questioned whether the H. pylori colonization could offer benefits to its human host (1). Infection with H. pylori can be diagnosed with endoscopic techniques (staining, culture or urease test) or non-endoscopic techniques (C13/C14-urea breath test, serology, molecular biology and antigen detection).
in stools). Both types can reliably detect the infection and evaluate treatment success\(^{(11)}\).

First-line therapy schemes, which currently combine two antibiotics and a proton pump inhibitor, achieve reasonably high cure rates. Yet, sometimes, the infection is refractory, making necessary to consider alternative schemes. In addition, even when the pathogen has been successfully eradicated, recurrence is possible\(^{(16,24)}\).

The purpose of this retrospective study was to determine if recurrence of *H. pylori* infection occurs in the long-term – 5 years or more after confirmed eradication – in patients with peptic ulcer. Moreover, if recurrence occurred, we sought to determine at which rate.

**METHODS**

In this retrospective and longitudinal study, the population consisted of patients with peptic ulcer disease treated in the period from 1990 to 2000. The data were collected from an electronic database at the Gastroclinica Cascavel, a referral center in Western Paraná, Brazil. The patients were selected based on codes for peptic ulcer disease presented in the 9th and 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD).

To be included in the sample, patients should: I) have a history of duodenal or gastric ulcer (or ulcer scar) on esophagogastroduodenoscopy (EGD); II) have a history of infection with *H. pylori* prior to treatment, confirmed by histological analysis according to the Sydney System and urease test; III) have tested negative for *H. pylori* on the same tests approximately three months after treatment, indicating successful eradication of the pathogen; and IV) have been followed for at least 5 years after eradication. To test for *H. pylori* infection – at baseline, at the control evaluation after treatment, and during the follow-up – histological analyses graded according to the Sydney System and urease test; were performed on biopsy fragments (two from the anterior and posterior antrum wall and two from the distal and proximal corpus).

Patients without confirmed eradication of *H. pylori* or patients that became positive for *H. pylori* in less than 5 years after the eradication were excluded from the study.

The sample was characterized regarding sex, age and type of mucosal lesion initially presented at EGD. The schemes used to treat the infection were either a triple regimen for 14 days (amoxicillin 1g/day + clarithromycin 500mg/day + proton pump inhibitor) or a bismuth regimen for 14 days (bismuth compound + metronidazole 500 mg/day + tetracycline 500 mg/day, sometimes with addition of a proton pump inhibitor). The recurrence of *H. pylori* and the presence of active ulcers during the follow-up were verified. Use of non-steroidal anti-inflammatory drugs (NSAIDs) was investigated in patients with new ulcers.

The statistical analysis was performed with the software QuickCalcs (GraphPad Software, Inc. 2015, La Jolla, California, USA). Categorical variables were expressed as relative and absolute values, while numerical variables were expressed as mean and standard deviation (SD). Fisher’s exact test was used to detect statistically significant differences between categorical variables. A two-tailed *P*-value of less than 0.05 was considered statistically significant.

The study protocol was previously approved by the Human Research Ethics Committee of Faculdade Assis Gurgacz and filed under case number 868.091.

**RESULTS**

The sample consisted of 201 patients that satisfied the study criteria. The average age was 47.1 (SD ±7) years and most individuals were male (n=113; 56.2%). All patients tested positive at baseline for *H. pylori* infection on histological examination and urease test. The majority had active ulcers documented at baseline EGD (n=146; 72.6%). On the other hand, ulcer scar was found in almost one-third (n=55; 27.4%) of the patients. A large proportion of the individuals had the peptic ulcer disease located at duodenum (n=149; 74.1%). (Table 1).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>n = 113 (56.2%)</td>
</tr>
<tr>
<td>Female</td>
<td>n = 88 (43.8%)</td>
</tr>
<tr>
<td><strong>Age in years (mean)</strong></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>47.1 (SD ±7)</td>
</tr>
<tr>
<td>Males</td>
<td>51 (SD ±7.6)</td>
</tr>
<tr>
<td>Females</td>
<td>42.2 (SD ±6.2)</td>
</tr>
<tr>
<td><strong>Lesion documented on EGD</strong></td>
<td></td>
</tr>
<tr>
<td>Duodenal ulcer</td>
<td>n = 104 (51.7%)</td>
</tr>
<tr>
<td>Duodenal ulcer scar</td>
<td>n = 45 (22.4%)</td>
</tr>
<tr>
<td>Gastric ulcer</td>
<td>n = 42 (20.9%)</td>
</tr>
<tr>
<td>Gastric ulcer scar</td>
<td>n = 10 (5%)</td>
</tr>
</tbody>
</table>

EGD: esophagogastroduodenoscopy; SD: standard deviation.

The treatment employed to eradicate the *H. pylori* were either a triple regimen or a bismuth regimen. All patients tested negative for *H. pylori* in histological analyses and urease test after therapy. The average interval between treatment and control evaluation was 81.3 days (SD ±12.5 days).

The patients were followed for 5 or more years after eradication. Patients with early recurrence – prior to 5 years since the eradication – are not part of this study. The mean time of follow-up was 8.1 years (SD ±2.4 years) with a median of 7.6 years.
On the follow-up, 180 (89.6%) of the 201 patients continuously tested negative for *H. pylori* on histopathological examination and urease test, while 21 (10.4%) patients became positive for *H. pylori* infection.

In two-thirds of the patients with infection recurrence, active ulcers were found during follow-up (n=14; 66.7%). These patients had the new ulcers identified at EGD at same time the reinfection was documented, and were not taking NSAIDs. No patients in the group without *H. pylori* recurrence had new ulcers during follow-up. The relation between *H. pylori* recurrence and active ulcers on follow-up was statistically significant ($P<0.05$). On the EGD, the 21 patients with *H. pylori* recurrence presented: duodenal ulcer (n=11; 52.4%); duodenal ulcer scar (n=6; 28.6%); gastric ulcer (n=2; 9.5%); gastric ulcer scar (n=1; 4.8%); or both duodenal and gastric ulcer (n=1; 4.8%). (Table 2).

**TABLE 2.** Relation between *H. pylori* recurrence and active peptic ulcer during follow-up, of 201 patients with peptic ulcer disease treated for *H. pylori* infection, in the period of 1990-2000, and followed for 5 years or more after successful *H. pylori* eradication

<table>
<thead>
<tr>
<th><em>H. pylori</em> recurrence on follow-up</th>
<th>Active peptic ulcer on follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>n = 180 (89.6%)</td>
</tr>
<tr>
<td>Yes</td>
<td>n = 7 (3.5%)</td>
</tr>
<tr>
<td>Yes</td>
<td>n = 14 (7%)</td>
</tr>
</tbody>
</table>

Statistically significant result ($P<0.05$).

**DISCUSSION**

Treatment for peptic ulcer was for many decades surgical. In fact, gastrectomy (Billroth I and II) was introduced already in 1888. Later techniques, such as partial gastrectomy, antrectomy and vagotomy (posteriorly, selective and highly selective vagotomy), improved outcomes, but the surgical approach continued to be associated with high levels of morbidity and mortality.

Throughout the twentieth century, the pathophysiology and treatment of peptic ulcer were widely discussed, leading to the emergence of several theories. In 1972, James Black first identified histamine receptors in parietal cells. The ensuing development of antacid drugs capable of blocking these receptors opened up new horizons in the treatment of peptic ulcer. Black was consequently awarded the Nobel Prize in Physiology or Medicine in 1988. Nevertheless, the rediscovery of *H. pylori* and its role in gastrointestinal disease caused a major impact on the management of this condition. Previously associated with high rates of mortality or severe complications (such as perforation, hemorrhage and stenosis), peptic ulcer is now treated effectively with antibiotics and oral antacids, while surgery has become restricted to treatment of complications. Drug therapy initially consisted of bismuth regimens that developed into treatment with a proton pump inhibitor (such as omeprazole) or a histamine receptor blocker. However, new challenges in the management of this condition have appeared.

This study allowed verifying if recurrence of *H. pylori* infection occurs in the long-term – 5 years or more after confirmed eradication – in patients with peptic ulcer, treated in the period from 1990 to 2000. The sample was composed by individuals with an average age of 47 years, with a slightly predominance of males. Most patients had active ulcers documented at baseline EGD. This finding is probably related with an increase in the search for medical attention during symptomatic periods of the disease.

The patients received either a triple regimen (amoxicillin, clarithromycin and a proton pump inhibitor) or a bismuth regimen (bismuth compound, metronidazole, and tetracycline, sometimes with a proton pump inhibitor) for *H. pylori* eradication. However, since only patients with confirmed eradication – through histological examination and urease test – joined the study, was impossible to compare efficacy between treatments in eradicating the *Helicobacter*. The control evaluation to document eradication was performed an average of 81 days after treatment.

This study had focused on long-term recurrence. The patients were followed for an average of 8 years, showing that, recurrence can occur even if the patient had eradication confirmed and had remained free of *H. pylori* during the first years of follow-up after treatment. Due to the study design (regarding confirmed eradication and exclusion of patients with early recurrence), is most probable that patients whom became positive again suffered true reinfection. However, only molecular methods can accurately differ between reinfection and recrudescence.

The recurrence rate of *H. pylori* found (10.5%) is close to figures reported in other Brazilian studies. In these researchers, recurrence rate ranged between 5% and 20%. However, it should be noted that these studies are heterogeneous. Generally, research on recurrence rate of *H. pylori* were aimed on the first 5 years post-treatment.

The *H. pylori* recurrence is closely associated with an increase in the incidence of new ulcers. This is supported by our finding of new ulcers in two-thirds of the patients with *H. pylori* reinfection. Reinforcing this idea, no patients had active ulcers during follow-up on the group without reinfection. The association between reinfection and new ulcers was statistically significant ($P<0.05$).

This study suffered with limitations, most due to its retrospective design. The patients were tested at heterogeneous intervals during follow-up, therefore, was not possible to describe the interval between eradication and reinfection/development of new ulcers. For example, if a patient had a 3 years interval between tests, with *H. pylori* recurrence documented on the later evaluation, was not possible to determine when, on this 3 years interval, the reinfection really occurred. Moreover, the incidence of active ulcers was high among patients with reinfection – such patients may have been inclined to seek medical attention due to symptoms, potentially leading to an overestimation of the recurrence rate.

Despite its limitations, few studies were aimed to determine the recurrence rate among Brazilian patients.
5 years or more after eradication. Our findings suggest that, despite the treatment had effectively reduced the incidence of gastrointestinal ulcer in the long-term – only 7% of the sample had new ulcers – the risk of recurrence cannot be discarded. Even long years after _H. pylori_ eradication, re-infection or recrudescence should be suspected, especially if the patients became symptomatic again. The best way to follow patients with peptic ulcer after successful treatment for _H. pylori_ is discussable. Ideally, the cost-effectiveness of subsequent medical interventions, the local recurrence rate and the individual risk of complications should be considered. Other long-term studies on recurrence of _H. pylori_, especially with prospective design, can help establish follow-up criteria for patients with peptic ulcer and determine to what extent therapy is protective over long periods.

**CONCLUSION**

The recurrence of _H. pylori_ in patients with peptic ulcer can occur in the long-term – even if the infection had been successfully eradicated and the patients had remained negative during the initial years of follow-up. The recurrence rate of _H. pylori_ was 10.4%. Two-thirds of the patients with _H. pylori_ recurrence also experienced new ulcers. Additionally, patients that had remained negative for _H. pylori_ did not present active ulcers during follow-up.

**Authors' contributions**

Fernandes YCF: study design, data collection, statistical analysis, manuscript writing. Bonatto GR: study design, data collection. Bonatto MW: study design, critical review and corrections of manuscript.

---

**REFERENCES**

11. Doria, JM: Study design, critical review and corrections of manuscript. Bonatto MW: study design, critical review and corrections of manuscript.